Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 September 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

The right idea for the wrong patient: results of a national survey on stopping PPIs

The Right Idea for the Wrong Patient: Results of a National Survey on Stopping PPIs

News image

Recent studies have linked proton pump inhibitor use to serious adverse effects, including bone fracture, chronic kidney disease, dementia, and ischemic stroke.

Although it remains unclear whether proton pump inhibitors truly cause these adverse effects, this potential has forced physicians to carefully consider the safety 
and utility of long-term PPI use in their patients, a topic included in the American Board of Internal Medicine Foundation’s Choosing Wisely campaign.

Using case vignettes, Dr Jacob Kurlander and colleagues from Michigan, USA evaluated internists’ willingness to stop proton pump inhibitor varies according to drug indication.

In 2013, the reseachers conducted an online, cross-sectional survey of a representative sample of the American College of Physicians using their Internal Medicine Insider Research Panel.
Respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor
Clinical Gastroenterology & Hepatology

Physicians spending 25% of their time in direct patient care were invited.

The research team developed 3 patient vignettes, all featuring a 70-year-old woman prescribed omeprazole, 20 mg daily, and recently diagnosed with osteopenia,  increasing her risk of bone fracture, a reported PPI adverse effect.

The vignettes differed in proton pump inhibitor indication:  gastroesophageal reflux disease  well controlled for years with normal upper endoscopy;  prevention of 
upper gastrointestinal bleeding  while on low-dose aspirin  and warfarin, otherwise asymptomatic; or  prevention of upper gastrointestinal bleeding while on low-dose 
aspirin alone with a history of nonsteroidal anti-inflammatory drug–related peptic ulcer disease 10 years prior, otherwise asymptomatic.

The 3 vignettes represented low-, moderate-, and high-risk for upper gastrointestinal bleeding, respectively, and bleeding risk was not explicitly stated in the vignettes.

Respondents were presented at random with 2 of the 3 patient vignettes to minimize respondent fatigue.

For each vignette, the researchers asked respondents how likely they would be to stop proton pump inhibitor on a 1–7 Likert-type scale.

The researchers also asked participants how concerned they were about long-term pump inhibitor indication adverse effects on a 1–7 Likert-type scale.

The reserchers hypothesized that physicians would be most likely to recommend proton pump inhibitor stopping in the patient with gastroesophageal reflux disease.

A total of 487 of 914 invited participants completed the survey. 

The team found that the median age was in the 5th decade of life, and 30% were female.

The researchers noted that a total of 22% were trainees, 58% practiced general medicine, 2% gastroenterology, and 18% another subspecialty.

The team observed that on a 1–7 scale, most physicians reported moderate concern about PPI adverse effects.

For the patient vignette with high risk for upper gastrointestinal bleeding , 62% of respondents would stop the proton pump inhibitor, compared with 47% for the 
moderate-risk vignette, and only 32% for the low-risk vignette.

The team noted that respondents shown the moderate-risk vignette were 1.47 times  more likely to stop proton pump inhibitor relative to the low-risk vignette, whereas respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor relative to the low-risk.

Dr Kurlander's team concludes,  "For every 1-point increase on the 7-point scale of concern about proton pump inhibitor adverse effects, probability of stopping proton pump inhibitor increased by 11%."

"Older physician age  and being a current trainee  were both independently associated with a lower probability of stopping." 

Clin Gastroenterol Hepatol 2017: 15: 1475–1476
14 September 2017

Go to top of page Email this page Email this page to a colleague

 23 September 2017 
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
 23 September 2017 
Highly bioavailable silibinin nanoparticles inhibit HCV infection
 22 September 2017 
MRI for liver metastatic colorectal cancer
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 21 September 2017 
Predicting mucosal healing in treated celiac disease patients
 21 September 2017 
Antireflux surgery and recurrence of GERD
 21 September 2017 
Adenomatous colorectal polyps in young cancer survivors
 20 September 2017 
Rifaximin and spontaneous bacterial peritonitis in cirrhosis
 20 September 2017 
Omega-3 PUFA and colorectal cancer survival
 20 September 2017 
Beta-blockers and cardiopulmonary exercise testing in liver disease
 19 September 2017 
Birth outcomes in children fathered by men treated with azathioprine
 19 September 2017 
Risk of death and statins in alcoholic cirrhosis
 19 September 2017 
Hospital-readmission risk
 18 September 2017 
Ethnic disparities and Hep C survival
 18 September 2017 
Depression and celiac disease in the USA
 18 September 2017 
Health care services in IBD
 15 September 2017 
Hemidesmosome integrity and colorectal cancer
 15 September 2017 
Herpes zoster vaccination in IBD
 15 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 14 September 2017 
National survey on stopping PPIs
 14 September 2017 
Psychological impact of IBD
 14 September 2017 
Bile tree pathology in patients presenting with gallbladder disease
 13 September 2017 
Predicting clinical outcome in colorectal cancer
 13 September 2017 
Oral contraceptives increases the risk of IBD
 13 September 2017 
Mortality in cirrhosis
 12 September 2017 
Genetic factors and tobacco in IBD
 12 September 2017 
Predictors of colectomy in ulcerative colitis
 12 September 2017 
Low birthweight and pediatric NAFLD
 11 September 2017 
Proteomic analysis of IBD
 11 September 2017 
New therapies to manage Hep B
 11 September 2017 
Ethnic disparities for chronic Hep C survival
 08 September 2017 
Antibiotics and diverticulitis
 08 September 2017 
Improving adherence to colorectal cancer screening
 08 September 2017 
Preoperative workup for colorectal cancer
 07 September 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 07 September 2017 
Outreach to improve colorectal cancer screening
 07 September 2017 
Nicotine chewing gum after colorectal surgery
 06 September 2017 
Novel candidate risk genes for IBD
 06 September 2017 
PPI use and chronic kidney disease
 06 September 2017 
Colorectal cancer surgery in the very elderly patient
 05 September 2017 
Unprovoked Venous Thromboembolism and occult cancer
 05 September 2017 
Hep E seroprevalence and hemodialysis
 05 September 2017 
Antibody tests and detecting celiac disease
 04 September 2017 
Acute pancreatitis and health related quality of life
 04 September 2017 
Infliximab treatment and eHealth in IBD
 04 September 2017 
Contrast-enhanced ultrasound for diagnosis of liver cancer
 01 September 2017 
Late recurrence of Barrett’s esophagus after eradication
 01 September 2017 
Thalidomide ine children with IBD
 01 September 2017 
Occult cancer screening with unprovoked venous thromboembolism
 31 August 2017 
Asthma and IBD development
 31 August 2017 
Environmental factors and IBD
 31 August 2017 
Management of noncardiac chest pain
 30 August 2017 
Diet and increased flares in patients with ulcerative colitis in remission
 30 August 2017 
Induction of remission in pediatric Crohn's disease
 29 August 2017 
Reducing antibody formation against TNF antagonists in IBD
 29 August 2017 
Epidemiological changes of chronic hepatitis
 28 August 2017 
Hyperuricemia and NAFLD activity score
 28 August 2017 
Therapy for acute variceal hemorrhage
 28 August 2017 
Colectomy rates in ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us